Notifications
Back

"We are dedicated to improving the lives of cancer patients by

enabling treatment options that go beyond today's standard of care"

"We are developing transformational gene therapy

for patients who have no options"

"Our first-in-class drug candidates are designed to 

overcome the unconquered Pan K-RAS cancer"

“Life is a phenomenon of gene expression, and its imbalance causes most of the diseases we know. The most effective tool to correct this imbalance is inevitably ‘gene’. Therefore, gene therapy technology is axiomatically the most effective treatment strategy that can fundamentally treat many diseases that were incurable in the past. We earnestly wish that the gene therapy technology we pursue will let us overcome life-threatening diseases in the near future.”



 Prof. Suk Chul Bae, CEO of GeneCraft 

About GeneCraft

GeneCraft is a pre-clinical-stage biotech company dedicated to improving treatment and clinical
outcomes for patients through gene therapy that harness the innate oncogene defense system.

Professor Sukchul Bae

Founder and Co-CEO

30+ years of research on cancer treatment effect of RUNX3 

(1991 – Now) 


Professor, College of Medicine, Chungbuk National University 


Director, Oncology Research Center, Chungbuk National University 


Director, Creative Research Task of the Ministry of Science and Technology 


Bio industry member of the National Science and Technology Committee


 Researcher, International Center for Infectiology Research 


Researcher, Kyoto University 


Pharm.D., Seoul National University 


Scientist of the Year award (2002) 


Best Presentation Award – International Journal of Oncology

Dr. Hongseok Ji

Co-CEO

Top expert in the field of biopharmaceutical production and Quality by Design (QbD)


Chief Innovation Officer, Samsung Bioepis


Expert Researcher, CTO Strategy Team, Samsung Advanced Institute of Technology


Advisor for Quality by Design (QbD), Korean Ministry of Food and Drug Safety 


PhD University of Tokyo

CTO Dr. Yousoub Lee

Visiting professor Chungbuk National University Visiting professor


Researcher Gil-Yeo Lee Cancer Diabetes Research Institute


PhD Chunabuk National University

СВО Seoungyeol Lee

CEO Huebrain


CSO PharmGen Science


Lafayette College

CSO Professor Woojin Kim

Assistant Professor Seoul National University


Specialist Doctor of Dentistry, Seoul National University


Visiting scholar Harvard-MIT


Patent attorney Pharmaceutical bio


CFO Soohyuck Kim

CFO Bokwang Group


Executive Samsung SDS / Corning FSA


MBA Berlin FU Sogang University


CCRO Kyoungmi Jung

Master CPM Amorepacific


Preclinical / clinical development Taepyeongvang


Researcher National Institute of Food and Drug Safety Evaluation


Masters Seoul National University

VPI Dr. Myungeun Lee

Scientist II, Sorrento Therapeutics


Post doc / Staff Scientist Washington University School of Medicine in Saint Louis


Post doc Georgia State University


PhD Institut Pasteur Korea/ Sungkyunkwan university

Technical Features

GeneCraft is pioneering the field of gene therapy for cancer patients with K-RAS mutation. Our pipeline is designed to unlock the next level of oncology by building on the most recent advances in gene therapy. GeneCraft’s lead program is focused on transforming the treatment paradigm in K-RAS mutated lung cancer by orchestrating gene driven, innate oncogene defense system.

Technology 1.

RX001 is the first-in-class treatment for Pan K-RAS mutated lung cancer.

Technology 2.

RX001 distinguishes abnormal K-RAS mutated cancer cells from normal cells and selectively induces the death of the cancer cells. 

Technology 3.

With its Ubi-AAV Platform, GeneCraft is able to craft gene contents into new gene therapeutics. 

Published
Papers

Cloning, mapping and expression of PEBP2αC, a third gene encoding the mammalian Runt domain

Causal relationship between the loss of RUNX3 expression and gastric cancer

Runx3 Inactivation Is a Crucial Early Event in the Development of Lung Adenocarcinoma

RUNX3 regulates cell cycle-dependent chromatin dynamics by functioning as a pioneer factor of the restriction-point

The RUNX family: developmental regulators in cancer

Read More 

- Tumor suppressor activity of RUNX3 “2004, Oncogene”
- Runx3 is required for the differentiation of lung epithelial cells and suppression of lung cancer “2010, Oncogene”
- How do K-RAS activated cells evade cellular defense mechanisms? “2015, Oncogene”
- Runx3 plays a critical role in restriction-point and defense against cellular transformation “2017, Oncogene”
- Functional relationship between p53 and RUNX proteins”2018, Journal of Molecular Cell Biology”

News 

Notice


Contact

HQ : S19-102, 1, Chungdae-ro, Seowon-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea (Chungbuk National University) 

Clinical Trial Center :  #649, 6th fl. Keumgang IX Tower, Dongtancheomdan-1ro 27, Hwasung Gyeonggi Provice

Research Exchange Center : 623, Teheran-ro, Gangnam-gu, Seoul, Republic of Korea

Submit

GeneCraft

Copyright ⓒ GeneCraft 2022